174 related articles for article (PubMed ID: 25674718)
1. Dose-adjusted EPOCH-R for Burkitt lymphoma.
Hoelzer D
Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
[No Abstract] [Full Text] [Related]
2. Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
Jindal N; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Br J Haematol; 2020 Sep; 190(6):e362-e363. PubMed ID: 32614462
[No Abstract] [Full Text] [Related]
3. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
4. A rare cause of gastric malignancy: Burkitt's lymphoma.
Doycheva I; Tanner S; Zhou D; Samadder NJ
Endoscopy; 2013; 45 Suppl 2 UCTN():E432-3. PubMed ID: 24338176
[No Abstract] [Full Text] [Related]
5. Conventional dose intensive immunochemotherapy regimen in an adult patient with very late relapse of Burkitt's lymphoma.
Italiano A; Peyrade F; Soler C; Cardot N; Thyss A
J Chemother; 2007 Apr; 19(2):236-8. PubMed ID: 17434838
[No Abstract] [Full Text] [Related]
6. DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
Hertzberg M; Joske DJL; Gandhi MK
J Clin Oncol; 2020 Nov; 38(31):3722-3723. PubMed ID: 32931401
[No Abstract] [Full Text] [Related]
7. Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
Lim KJC; Filshie R
Lancet Haematol; 2023 Dec; 10(12):e942-e943. PubMed ID: 37922924
[No Abstract] [Full Text] [Related]
8. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Frick M; Dörken B; Lenz G
Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
[TBL] [Abstract][Full Text] [Related]
9. Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Hunter NB; Vogt S; Ambinder RF
Oncology (Williston Park); 2017 Dec; 31(12):872-7, 884. PubMed ID: 29297171
[TBL] [Abstract][Full Text] [Related]
10. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
11. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
12. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
Jaradat JM; Potluri A; Bilodeau EA
Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
[TBL] [Abstract][Full Text] [Related]
13. Treatment of progression during reductive prophase for paediatric primary mediastinal B-cell lymphoma using dose-adjusted EPOCH chemotherapy.
Chen RL; Chuang SS; Lu YH
Pediatr Blood Cancer; 2011 Jul; 56(7):1149-50. PubMed ID: 21337677
[No Abstract] [Full Text] [Related]
14. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Maruyama D
Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
[No Abstract] [Full Text] [Related]
15. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Crosswell HE; Bergsagel DJ; Yost R; Lew G
Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
[TBL] [Abstract][Full Text] [Related]
16. [How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?].
Tobinai K
Rinsho Ketsueki; 2012 Jun; 53(6):609-17. PubMed ID: 22790636
[No Abstract] [Full Text] [Related]
17. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
[No Abstract] [Full Text] [Related]
18. AIDS-lymphoma (ARL): one more step along the way.
Levine AM
Blood; 2013 Nov; 122(19):3244-6. PubMed ID: 24203926
[TBL] [Abstract][Full Text] [Related]
19. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
[No Abstract] [Full Text] [Related]
20. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Fowler NH
Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
[No Abstract] [Full Text] [Related]
[Next] [New Search]